MAB 170H.82 - AN EVALUATION OF A NOVEL PANADENOCARCINOMA MONOCLONAL-ANTIBODY LABELED WITH TC-99(M) AND WITH IN-111

被引：30

作者：

MCEWAN, AJB

MACLEAN, GD

HOOPER, HR

SYKES, T

MCQUARRIE, SA

GOLDBERG, L

BODNAR, DM

LLOYD, SL

NOUJAIM, AA

机构：

[1] Department of Nuclear Medicine, Cross Cancer Institute, Edmonton, AB

[2] Department of Medicine, Cross Cancer Institute, Edmonton, AB

[3] Department of Medicine, Edmonton, AB

[4] University of Alberta, Edmonton, AB

[5] Biomira Inc, Edmonton, AB

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1992年 / 13卷 / 01期

关键词：

D O I：

10.1097/00006231-199201000-00003

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

A novel method for generating monoclonal antibodies against synthetic tumour-associated glycoconjugates has been developed. One of these monoclonal antibodies, designated 170H.82, was derived against the TF antigen and has been shown in vitro to have a wide range of reactivity with adenocarcinoma. This antibody has been labelled with In-111 and Tc-99m and has been evaluated in pilot clinical trials involving 48 patients with a range of adenocarcinoma. Overall clinical accuracy with the radiolabelled antibody was 92%, with the antibody appearing to have particular clinical utility in gynaecological and breast cancers. Single photon emission computed tomographic (SPECT) imaging was shown to improve the quality of the images and to improve the diagnostic sensitivity. We believe that this unique antibody, labelled with Tc-99m, appears to offer promise for routine clinical use in the evaluation of patients with a range of primary and metastatic adenocarcinoma.

引用

页码：11 / 19

页数：9

共 26 条

[1]

Maclean G.D., Noujaim A.A., McEwan A., Suresh M.R., Sykes T.R., Marcushamer S., Longenecker B.M., A novel strategy to derive monoclonal antibodies for successful imaging of cancers in humans, Cellular Basis of Immune Modulation, pp. 587-599, (1989)

[2]

Maclean G.D., McEwan A., Noujaim A.A., Sykes T.R., Suresh M.R., Catz Z., Hooper H.R., Longenecker B.M., A novel strategy for cancer immunoscintigraphy. Antibody, Immunoconjug Radiopharmaceut, 2, pp. 15-27, (1989)

[3]

Maclean G.D., McEwan A., Noujaim A.A., Hooper H.R., Sykes T.R., Bodnar D.M., Lloyd S., Golberg L.E., Longenecker B.M., Two novel monoclonal antibodies have potential for gynecologic cancer imaging. Antibody, Immunoconjug Radiopharmaceut, (1991)

[4]

Larson S.M., Clinical radioimmunodetection, 1978-1988: Overview and suggestions for standardization of clinical trials, Cane Res 1990, 50, pp. 892s-898s

[5]

Colcher D., Carrasquillo J.A., Esteban J.M., Sugarbaker P., Reynolds J.C., Siler K., Bryant G., Larson S.M., Schlom J., Radiolabelled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients, Nucl Med Biol, 14, pp. 251-262, (1987)

[6]

Goldenberg D.M., Guest editorial: Current status of cancer imaging with radiolabelled antibodies, J Cane Res Clin Oncol, 113, pp. 203-208, (1987)

[7]

Springer G.F., T and Tn, general carcinoma autoantigens, Science, 224, pp. 1198-1206, (1984)

[8]

Rhodes B.C., Zamora P.O., Newell K.D., Valdez E.F., Technetium-99m labelling of murine monoclonal antibody fragments, J Nucl Med, 27, pp. 685-693, (1986)

[9]

Schwarz A., Steinstrasser A., A novel approach to Tc-99m- labelled monoclonal antibodies, J Nucl Med, 28, (1987)

[10]

Longenecker B.M., Willans D.J., Maclean G.D., Selvaraj S., Suresh M.R., Noujaim A.A., Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers, J Natl Cancer Inst, 78, pp. 489-496, (1987)

← 1 2 3 →